跳至主要内容
临床试验/PER-014-03
PER-014-03已完成1 期

A MULTICIENTRIC, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-0767 TO PATIENTS WITH TYPE 2 DIABETES THAT PRESENT INACCURATE GLYCEMIC CONTROL IN THE COMBINED THERAPY OF METFORMIN AND SULFONILUREA.

MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2003年3月12日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 0(—)

入选标准

  • Age> 21 and <78 years.
  • In stable doses of metformin and sulfonylurea for at least 2
  • weeks before Visit 2 / Week -6.
  • Understanding of study procedures and agreement of
  • participate in the study through informed consent

排除标准

  • Patients with a history of type 1 diabetes mellitus and / or history
  • of ketoacidosis and / or C-peptide <0.8 ng / mL (<0.26 nmol / L).
  • Patients with the following treatments for diabetes during the
  • 8 weeks prior to Visit 1.
  • Patients with a history of allergy, intolerance or hypersensitivity to troglitazone, rosiglitazone, pioglitazone or other PPAR-agonists and including a history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments.

研究者

发起方
MERCK SHARP & DOHME PERU S.R.L.,

相似试验